To compare the efficacy of intratympanic injections of methylprednisolone (ITMP) and intratympanic injections of gentamicin (ITG) to control the symptoms of Ménière’s disease and to evaluate their effect on hearing level.
Study Design
A historical cohort study.
Setting
Tertiary referral center.
Subjects and Methods
Eighty-nine patients affected by Ménière’s disease were included in this study, of whom 47 were treated with ITG and 42 were treated with ITMP. Two periods of follow-up were considered: 0 to 6 months and 6 to 12 months after the intratympanic injections (ITI). Mean outcome measurements consisted of control of vertigo attacks, tinnitus, and aural fullness; pure-tone average (PTA); and speech discrimination score (SDS).
Results
The 2 groups had the same number of vertigo spells per month before ITI (P = .883). Six to 12 months after ITI, 82.9% of the ITG group and 48.1% of the ITMP group achieved complete control of vertigo (P = .004). There was better control of tinnitus and aural fullness with ITG than with ITMP (P ≤ .002). The 2 groups had a statistically significant difference in hearing level before ITI (P ≤ .001). This difference was no longer present 6 to 12 months after ITI (P > .05).
Conclusion
Intratympanic injections of gentamicin are more efficient than ITMP in controlling the symptoms of Ménière’s disease. The 2 groups ended up without a difference in hearing level after ITI. According to these findings, administrating ITMP to control Ménière’s disease seems to be less beneficial than ITG.
RauchSD. Clinical hints and precipitating factors in patients suffering from Ménière’s disease. Otolaryngo Clin North Am. 2010;43:1011-1017.
2.
GuildS. The circulation of the endolymph. Am J Anat. 1927;39:57.
3.
PortmannG. Vertigo: surgical treatment by opening of the saccus endolymphaticus. Arch Otolaryngol. 1927;6:309.
4.
DandyWE. Meniere’s disease: its diagnosis and method of treatment. Arch Surg. 1928;16:1127-1152.
5.
BottrillIWillsAD. Intratympanic gentamicin for unilateral Menière’s disease: results of therapy. Clin Otolaryngol. 2003;28:133-141.
6.
FowlerEP. Streptomycin treatment of vertigo. Trans Am Acad Opthlmol Otolaryngol. 1948;52:239-301.
7.
SchuknechtH. Ablation therapy in the management of Meniere’s disease. Acta Otolaryngol (Stockh). 1957;132:1-42.
8.
RudnickMDGinsbergIAHuberPS. Aminoglycoside ototoxicity following middle ear injection. Ann Otol Rhinol Laryngol. 1980;89(suppl 77):1-9.
9.
ParkJCohenG. Vestibular ototoxicity in the chick: effects of streptomycin on equilibrium and on ampullary dark cells. Am J Otolaryngol. 1982;6:117-127.
10.
DereberryMERaoVS. Ménière’s disease: an immune complex–mediated illness?Laryngoscope. 1991;101:225-229.
11.
BrookesGB. Circulating immune complexes in Ménière’s disease. Arch Otolaryngol Head Neck Surg. 1986;112:536-540.
12.
GutiérrezFMorenoPMSainzM. Relationship between immune complex and total hemolytic complement in endolymphatic hydrops. Laryngoscope. 1994;104:1495-1498.
13.
YooTJFloidRIshibeT. Immunologic testing of certain ear diseases. Am J Otol. 1985;6:96-101.
14.
YooTJ. Ethiopathogenesis of Ménière’s disease: a hypothesis. Ann Otol Rhinol Laryngol. 1984;93(suppl 113):6-12.
15.
Danckwardt-LillieströmNFribergUKinneforsA. Endolymphatic sacitis in a case of active Ménière’s disease: a TEM histopathological investigation. Ann Otol Rhinol Laryngol. 1997;106:190-198.
16.
DornhofferJLWanerMArenbergIK. Immunoperoxidase study of the endolymphatic sac in Ménière’s disease. Laryngoscope. 1993;103:1027-1034.
17.
JuhnSKLiWKimJY. Effects of stress related hormones on inner fluid homeostasis and function. Am J Otol. 1999;20:800-806.
18.
FukushimaMKitaharaTFuseYUnoYDoiKKuboT. Changes in aquaporin expression in the inner ear of the rat after i.p. injection of steroids. Acta Otolaryngol Suppl. 2004;(553):13-18.
19.
BirdPABeggEJZhangM. Intratympanic versus intravenous delivery of methylprednisolone to cochlear perilymph. Otol Neurotol. 2007;28:1124-1130.
20.
Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Ménière disease. Otolaryngol Head Neck Surg. 1995;113:181-185.
21.
Committee on Hearing and Equilibrium guidelines for the evaluation of hearing preservation in acoustic neuroma (vestibular schwannoma). American Academy of Otolaryngology–Head and Neck Surgery Foundation, Inc. Otolaryngol Head Neck Surg. 1995;113:179-180.
22.
CasaniAPPiaggiP. Intratympanic treatment of intractable unilateral Ménière disease: gentamicin or dexamethasone? A randomized control trial. Am J Otolaryngol. 2012;146(3):430-437.
23.
SennarogluLSennarogluGGurselB. Intratympanic dexamethasone, intratympanic gentamicin, and endolymphatic sac surgery for intractable vertigo in Ménière disease. Otolaryngol Head Neck Surg. 2001;125:537-543.
24.
ParnesLSSunAHFreemanDJ. Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application. Laryngoscope. 1999;109:1-17.
25.
SelivanovaOAGoueverisHVictorA. Intratympanic dexamethasone and hyaluronic acid in patient with low-frequency and Ménière associated sudden sensorineural hearing loss. Otol Neurotol. 2005;26:890-895.
26.
ItohASakataE. Treatment of vestibular disordersActa Otolaryngol Suppl. 1991;481:617-623.
27.
HirvonenTPPeltomaaMYlikoskiJ. Intratympanic and systemic dexamethasone for Ménière disease. ORL J Otorhinolaryngol Relat Spec. 2000;62:117-120.
28.
BarrsDMKeyserJSStallworthC. Intratympanic steroid injections for intractable Ménière disease. Laryngoscope. 2001;111:2100-2104.
29.
BarrsDM. Intratympanic injections of dexamethasone for long-term control of vertigo. Laryngoscope. 2004;114:1910-1914.
30.
DodsonKMWoodsonESismanisA. Intratympanic steroid perfusion for the treatment of Ménière disease: a retrospective study. Ear Nose Throat J. 2004;83:394-398.
31.
ChiaSHGamstACAndersonJP. Intratympanic gentamicin therapy for Ménière disease: a meta-analysis. Otol Neurotol. 2004;25:544-552.
32.
Cohen-KeremRKisilevskyVEinarsonTR. Intratympanic gentamicin for Ménière disease: a meta-analysis. Laryngoscope. 2004;114:2085-2091.
33.
ZhaiFLiuJPDaiCF. Evidence based modification of intratympanic gentamicin injections in patients with intractable vertigo. Otol Neurotol. 2010;31:642-648.
34.
Tran BaHPBernardPSchachtJ. Kinetics of gentamicin uptake and release in the rat comparison of inner ear tissues and fluids with other organs. J Clin Invest. 1986;77:1492-1500.
35.
XingGChenZWeiQ. Mitochondrial 12S rRNA A827G mutation is involved in the genetic susceptibility to aminoglycoside ototoxicity. Bio Chem Bio Phys Res Commun. 2006;346:1131-1135.
36.
GuanMXFischel-GhodsianNAttardiG. A biochemical basis for the inherited susceptibility to aminoglycoside ototoxicity. Hum Mol Genet. 2000;9:1787-1793.
37.
LiRGrienwaldJHYangLChooDI. Molecular analysis of mitochondrial 12S rRNA and tRNAser(UCN) genes in pediatric subjects with non syndromic hearing loss. J Med Genet. 2004;41:615-620.
38.
Lopez-BigasNRabionetRMartinezE. Mutations in the mitochondrial tRNASer(UCN) and in the GJB2 (connexin 26) gene are not modifiers of the age of onset or severity of hearing loss in Spanish patients with the 12S rRNAA1555G mutation. Am J Hum Genet. 2000;66:1465-1467.
39.
UsamiSIAbeSAkitaJ. Prevalence of mitochondrial gene mutations among hearing impaired patients. J Med Genet. 2000;37:38-40.
